Clinical trial NCT05769439: Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity
Official title: Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Incident Type 2 Diabetes
Incident Obesity
Keywords: hydroxymethylation
twin
monozygotic
dizygotic
fraternal
identical
Lead sponsor: Des Moines University
Sponsor class: OTHER
Collaborators: name: Indiana University
name: Penn State University
name: EpiGenTek, LLC
First posted: 2023-03-15
Enrollment: 126
Sex: MALE
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Below is the Parent Cohort Description:

The NHLBI Twin Study (NTS) is a prospective study of the genetic and environmental etiology of cardiovascular disease. Initiated in 1969, researchers recruited 514 white male twin pairs (i.e., 1,024 men) born between 1917 and 1927. The twins were roughly 50% monozygotic twin pairs (MZ) and 50% dizygotic twin pairs (DZ) and were middle-aged at baseline (1969-1973). The five research sites were Framingham, MA; San Francisco, CA; Davis, CA; Los Angeles, CA; and Indianapolis, IN. The participant inclusion criterion was the geographic proximity to the study sites (within 100 miles in New England and California, and within 200 miles of Indianapolis, Indiana). The twins received physical examinations based on the renowned Framingham Heart Study protocol.

Brief summary: The proposed discordant identical and fraternal twin study of incident type 2 diabetes and incident obesity is pivotal to public health because this study design compares diseased twins with their non-diseased co-twins for a better understanding of environment-induced hydroxymethylation independent of genetic influences as the novel biological mechanism underlying the diseases. By engaging students in the proposed co-twin control study, we will prepare our next generation of public health researchers to sustain our impact on public health across generations. The discovery of new environmentally and epigenetically therapeutic and preventive regimens will pave the way to fight against incident type 2 diabetes and incident obesity.

Detailed description: Hydroxymethylated cytosine (5hmC) in DNA is an epigenetic modification that regulates gene transcription. Type 2 diabetes (T2D) and obesity (OB) are diseases that are serious global public health challenges. Little is known about the role of 5hmC in the development of T2D and OB. In our exploratory study to investigate hydroxymethylation using a co-twin control design, we included three monozygotic twin pairs (MZ) discordant for incident T2D (iT2D) and five separate MZ pairs discordant for prevalent OB from our previous R21 (1R21HL127368-01) study of cardiovascular disease. Using circulating 5hmC as an aggregate surrogate for cumulative systemic hydroxymethylation, intriguingly, we found statistically significant, whole-genome differentially hydroxymethylated regions (DhMRs) related to iT2D and prevalent OB, respectively, after controlling for genetic variation in germline consisting of 3.2 billion base pairs, age-period-cohort effects, and multiple-testing. Due to the very limited sample size and lack of twin pairs discordant for incident OB (iOB) in our prior exploratory study, it is imperative to perform the prospective research in a relatively large sample to generate strong evidence. The National Heart, Lung, and Blood Institute (NHLBI) Twin Study is a well-characterized, 46-year follow-up study initiated in 1969. Leveraging existing rich resources in the NHLBI Twin Study and our established, multi-mechanism students' research engagement plan, we propose this R15 study. Our overall objectives are to characterize circulating 5hmC in relation to iT2D and iOB and to offer an excellent opportunity for students to be engaged in public health epigenome research. These objectives will be achieved by pursuing three specific aims: 1) measure whole genome hydroxymethylation (5hmC) in blood DNA samples; 2) test if DNA regions are differentially hydroxymethylated in relation to iT2D (aim 2-1) and iOB (aim 2-2) independent of germline and common environment; which, in turn, will identify novel differentially hydroxymethylated regions; and 3) characterize sociobehavioral and other environmental correlates of hydroxymethylation in literature-based candidate and novel DNA regions independent of germline and common environment. We will include all available twin pairs discordant for iT2D \[17 MZ and 20 dizygotic twin pairs (DZ)\] and separate twin pairs discordant for iOB (11 MZ pairs and 15 DZ pairs) from NHLBI Twin Study. The NHLBI Twin Study twins were born between 1917 and 1927, a period when 2 male MZ pairs and 4 male DZ pairs of twins were born per 1,000 live births. An illustrative example is that inclusion of our dMZ twin sample size is equivalent to that of at least 126,746 singletons. The significance of our study is to provide innovative evidence about iT2D and iOB-discriminating hydroxymethylation induced environmentally, which could impact disease prevention and treatment through the improvement of modifiable environmental factors. Our study will offer a unique opportunity for engaging medical and graduate students at the applicant's institute in the public health epigenome research.

Eligibility criteria: Inclusion Criteria:

In the NHLBI Twin Study, middle-aged, male, veteran twins were recruited at baseline (1969-1973).

Inclusion criteria include 1) an iT2D-discordant MZ and DZ twin pair in which one co-twin subsequently became diabetic after exam 3 through December 31, 2015 (i.e., case twin) while the other co-twin was nondiabetic on the index date (i.e., control twin); 2) an iOB-discordant MZ and DZ twin pair in which both co-twins were non-obese at exam 3 and one co-twin subsequently became obese55 after exam 3 through exam 5 (i.e., case twin) while the other co-twin was non-obese on the index date (i.e., control twin); 3) all twins must have blood DNA samples available and collected at least one year prior to the index date for each of the specific diseases (i.e., iT2D and iOB); and participant's date of birth, vital status, cause of death, death date, and date for the blood DNA collection are available.

Exclusion Criteria:

-

Primary outcomes:
measure: novel differentially hydroxymethylated regions (DhMRs) concerning incident type 2 diabetes
timeFrame: April 1, 2023 to December 31, 2023
measure: novel DhMRs concerning incident obesity
timeFrame: April 1, 2023 to December 31, 2023
measure: evidence-based DhMRs concerning incident type 2 diabetes
timeFrame: May1, 2022 to December 31, 2023
measure: evidence-based DhMRs concerning incident obesity
timeFrame: May1, 2022 to December 31, 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Des Moines
country: United States
facility: Des Moines University
state: Iowa
Study officials:
affiliation: Des Moines University
name: Jun Dai, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: